Induction of PD-L1 expression can be prevented by disrupting the tumor cell response to IFNγ signaling, rendering PD-1-PD-L1 blocking ineffective; however, this strategy represents a mechanism of resistance not only to the immune checkpoint, but also to anti-tumor immunity. The gene discussed is PDCD1; the disease is neoplasm.